臨床試驗

A Study of Mosliciguat in PH-ILD

NCT：NCT06635850 · ACTIVE_NOT_RECRUITING

NCT IDNCT06635850

狀態ACTIVE_NOT_RECRUITING

開始日期2024-10-29

SponsorPulmovant, Inc. (INDUSTRY)

First posted2024-10-10

Last updated2026-09-10

簡要摘要

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。